← Back

Wire · regulatory

FDA again turns back Capricor Duchenne cell therapy

Published

21 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA has rejected Capricor's cell therapy for Duchenne muscular dystrophy for a second time due to serious data integrity violations that compromised the study findings.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

FDA enforcement is tightening on data integrity in drug trials, forcing you to rigorously audit trial data if you want a chance at approval in rare disease therapies.

◆ Coverage

7 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdaduchenne-muscular-dystrophycell-therapydata-integrityregulatory-rejection